Clinical Trial Update: Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial update for Vorbipiprant (CR6086) combined with Balstilimab (AGEN2034) in stage IV refractory pMMR-MSS colorectal cancer and other metastatic G…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• Balstilimab (balstilimab)
• Vorbipiprant (CR6086)

Snippet

Sponsor: Rottapharm Biotech | Conditions: Refractory Metastatic Colorectal Cancer, Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING